Patents by Inventor Bernd Gerhartz

Bernd Gerhartz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kallikrein 7 modulators
    Patent number: 8309596
    Abstract: The present invention relates to the crystal structure of the serine protease kallikrein 7 and to the use of this crystal structure in drug discovery. The present invention also relates to compounds binding specifically to this active site of kallikrein 7.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: November 13, 2012
    Assignee: Novartis AG
    Inventors: Stefanie Flohr, Stefan Andreas Randl, Nils Ostermann, Ulrich Hassiepen, Frederic Berst, Ursula Bodendorf, Bernd Gerhartz, Andreas Marzinzik, Claus Ehrhardt, Josef Gottfried Meingassner
  • Kallikrein 7 modulators
    Publication number: 20100256144
    Abstract: The present invention relates to the crystal structure of the serine protease kallikrein 7 and to the use of this crystal structure in drug discovery. The present invention also relates to compounds binding specifically to this active site of kallikrein 7.
    Type: Application
    Filed: June 26, 2008
    Publication date: October 7, 2010
    Inventors: Stefanie Flohr, Stefan Andreas Randl, Nils Ostermann, Ulrich Hassiepen, Frederic Berst, Ursula Bodendorf, Bernd Gerhartz, Adreas Marzinzik, Claus Ehrhardt, Josef Gottfried Meingassner
  • Assay for ubiquitin mediated proteolysis
    Publication number: 20080038768
    Abstract: The present invention provides methods and compositions useful in the screening for agents that modulate activity of a deubiquitinating enzyme. In one embodiment, the invention relates to methods for measuring a deubiquitination activity comprising combining a deubiquitinating enzyme (DUB) with a substrate comprising a ubiquitin moiety and a fluorescently labeled compound under conditions allowing for deubiquitinating activity and measuring an altered fluorescence polarization and/or fluorescence lifetime of the released fluorescently labeled compound The invention also relates to a substrate library comprising peptides of the formula (Z)a(X)mK(X)n(Z)b useful e.g. for the determination of the substrate specificity of a deubiquitinating enzyme.
    Type: Application
    Filed: August 8, 2006
    Publication date: February 14, 2008
    Inventors: Ireos Filipuzzi, Bernd Gerhartz, Lukas Leder
  • Irreversible cysteine protease inhibitors of legumain
    Patent number: 7279550
    Abstract: Presented are compounds represented by the following general formulas (I) and (II), for inhibiting cysteine protease legumain for modulating associated disease states in subjects
    Type: Grant
    Filed: July 23, 2002
    Date of Patent: October 9, 2007
    Assignee: Probiodrug AG
    Inventors: André Niestroj, Ulrich Heiser, Bernd Gerhartz, Matthias Hoffmann, Hans-Ulrich Demuth
  • Irreversible cysteine protease inhibitors of legumain
    Publication number: 20060178315
    Abstract: Presented are compounds represented by the following general formulas (I) and (II), for inhibiting cysteine protease legumain for modulating associated disease states in subjects.
    Type: Application
    Filed: July 23, 2002
    Publication date: August 10, 2006
    Inventors: Andre Niestroj, Ulrich Heiser, Bernd Gerhartz, Matthias Hoffmann, Hans-Ulrich Demuth
  • Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
    Publication number: 20040214762
    Abstract: The present invention discloses a method for the modulation of the enzymatic activity of prolyl endopeptidase in various human tissues and their biological effect on intracellular inositol (1,4,5) triphosphate concentration. The present invention also discloses the potentiation of endogenous neurological and intracellular signaling cascades by inhibition of prolyl endopeptidase activity. This invention further discloses the amplification of substance P mediated stimulation of IP3 concentration by inhibition of proline endopeptidase activity. The effect of reduced PEP activity on second messenger concentration indicates a novel intracellular function of this peptidase, which has an important impact on cognitive enhancements due to PEP inhibition.
    Type: Application
    Filed: February 13, 2004
    Publication date: October 28, 2004
    Inventors: Hans-Ulrich Demuth, Bernd Gerhartz, Ingo Schulz